Adjuvant human papillomavirus vaccine to reduce recurrent cervical dysplasia in unvaccinated women: a systematic review and meta-analysis
Obstetrics & Gynecology, 2020•journals.lww.com
OBJECTIVE: To perform a systematic review and meta-analysis evaluating the efficacy of
adjuvant human papillomavirus (HPV) vaccination in preventing recurrent cervical
intraepithelial neoplasia (CIN) 2 or greater after surgical excision. DATA SOURCES:
Electronic databases (Cochrane, PubMed, EMBASE, MEDLINE, Scopus, and ClinicalTrials.
gov) were searched for studies comparing surgical excision alone to surgical excision with
adjuvant HPV vaccination for CIN 2 or greater. Studies published from January 1990 to …
adjuvant human papillomavirus (HPV) vaccination in preventing recurrent cervical
intraepithelial neoplasia (CIN) 2 or greater after surgical excision. DATA SOURCES:
Electronic databases (Cochrane, PubMed, EMBASE, MEDLINE, Scopus, and ClinicalTrials.
gov) were searched for studies comparing surgical excision alone to surgical excision with
adjuvant HPV vaccination for CIN 2 or greater. Studies published from January 1990 to …
OBJECTIVE:
To perform a systematic review and meta-analysis evaluating the efficacy of adjuvant human papillomavirus (HPV) vaccination in preventing recurrent cervical intraepithelial neoplasia (CIN) 2 or greater after surgical excision.
DATA SOURCES:
Electronic databases (Cochrane, PubMed, EMBASE, MEDLINE, Scopus, and ClinicalTrials. gov) were searched for studies comparing surgical excision alone to surgical excision with adjuvant HPV vaccination for CIN 2 or greater. Studies published from January 1990 to January 2019 were included.
METHODS:
A total of 5,901 studies were reviewed. The primary outcomes evaluated included: recurrence of CIN 2 or greater, CIN 1 or greater, and HPV 16, 18 associated CIN within 6–48 months. We used Covidence software to assist with screening, and meta-analysis was performed using Review Manager.
Lippincott Williams & Wilkins